Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (41-50 of 350) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|November 22, 2018
[Prostate cancer screening: Reasons of controversy]Gauthier Delporte, Arnauld Villers, Nicolas Penel
Bulletin Du Cancer|March 20, 2019
[Evolution of the regulatory framework in clinical research]Marie Vanseymortier, Julien Thery, Nicolas Penel
Bulletin Du Cancer|December 22, 2006
[Interest of imaging for the monitoring of a treated cancer: simplified use of likelyhood ratio. The example of soft tissue tumor]Sophie Taieb, Nicolas Penel, Luc Ceugnart
Critical Reviews in Oncology/Hematology|June 7, 2011
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?Nicolas Penel, Antoine Adenis, Guido Bocci
The Lancet. Oncology|November 17, 2012
Role of the investigator in phase 1 trials of anticancer drugsNicolas Penel, Antoine Adenis, Jacques Bonneterre
Current Opinion in Oncology|August 9, 2022
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)Elisabeth Gaye, Nicolas Penel, Loïc Lebellec
Bulletin Du Cancer|August 4, 2015
[Docetaxel and prostate cancer: Early but not too early]Nicolas Penel, Thomas Ryckewaert, Eric Yaovi Amela
Bulletin Du Cancer|June 14, 2024
[Oncology department: An ideal training site for 2nd-cycle medical students?]Nicolas Penel, Delphine Hudry, Pierre-Yves Cren
The New England Journal of Medicine|June 21, 2008
Imatinib as a possible cause of severe rhabdomyolysisNicolas Penel, Jean-Yves Blay, Antoine Adenis
Oncology|September 5, 2009
Imatinib in gastrointestinal stromal tumor: does treatment duration matter?Antoine Adenis, Nicolas Penel, Jean-Yves Blay
Pageof 35

Showing results (41-50 of 350) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|November 22, 2018
[Prostate cancer screening: Reasons of controversy]Gauthier Delporte, Arnauld Villers, Nicolas Penel
Bulletin Du Cancer|March 20, 2019
[Evolution of the regulatory framework in clinical research]Marie Vanseymortier, Julien Thery, Nicolas Penel
Bulletin Du Cancer|December 22, 2006
[Interest of imaging for the monitoring of a treated cancer: simplified use of likelyhood ratio. The example of soft tissue tumor]Sophie Taieb, Nicolas Penel, Luc Ceugnart
Critical Reviews in Oncology/Hematology|June 7, 2011
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?Nicolas Penel, Antoine Adenis, Guido Bocci
The Lancet. Oncology|November 17, 2012
Role of the investigator in phase 1 trials of anticancer drugsNicolas Penel, Antoine Adenis, Jacques Bonneterre
Current Opinion in Oncology|August 9, 2022
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer)Elisabeth Gaye, Nicolas Penel, Loïc Lebellec
Bulletin Du Cancer|August 4, 2015
[Docetaxel and prostate cancer: Early but not too early]Nicolas Penel, Thomas Ryckewaert, Eric Yaovi Amela
Bulletin Du Cancer|June 14, 2024
[Oncology department: An ideal training site for 2nd-cycle medical students?]Nicolas Penel, Delphine Hudry, Pierre-Yves Cren
The New England Journal of Medicine|June 21, 2008
Imatinib as a possible cause of severe rhabdomyolysisNicolas Penel, Jean-Yves Blay, Antoine Adenis
Oncology|September 5, 2009
Imatinib in gastrointestinal stromal tumor: does treatment duration matter?Antoine Adenis, Nicolas Penel, Jean-Yves Blay
Pageof 35